抗TFPI抗体MG1113在食蟹猴中的靶点介导药物处置模型预测人体药代动力学与药效学
本研究旨在通过食蟹猴药代动力学/药效学数据建立靶点介导药物处置(TMDD)模型,预测MG1113在人体中的药代动力学和药效学。MG1113在2.5-10 mg/kg剂量范围内静脉和皮下给药均呈现非线性药代动力学,且药物浓度与游离TFPI水平呈剂量-反应关系。该模型可用于模拟不同给药方案,为首个人体试验设计提供参考。
要点
- MG1113在食蟹猴2.5-10 mg/kg剂量范围内静脉和皮下给药均呈非线性药代动力学。
- TMDD模型可表征MG1113浓度与TFPI水平的剂量-反应关系。
- 该模型模拟的给药方案可为首次人体试验设计及后续临床试验剂量选择提供参考。
核心结论
- MG1113在食蟹猴中呈非线性药代动力学,TMDD模型可表征其浓度与TFPI水平的剂量-反应关系,并用于预测人体药代动力学和药效学。
研究设计与样本
- 在雄性食蟹猴中静脉和皮下给予MG1113(2.5、5、10 mg/kg),评估药代动力学和游离TFPI水平,建立PK/PD模型。
- 采用异速增长法计算人体PK参数,应用TMDD模型预测临床有效剂量。
主要发现
- MG1113在2.5-10 mg/kg剂量范围内静脉和皮下给药均呈现非线性药代动力学。
- MG1113浓度与TFPI水平的关系可通过TMDD模型表征为剂量-反应关系。
临床怎么用
- TMDD模型模拟的不同给药方案可用于支持MG1113的首次人体试验设计。
- 预测的临床有效剂量可为后续临床试验的剂量选择提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MG1113 is a human monoclonal antibody of tissue factor pathway inhibitor (TFPI) under development for prophylaxis for hemophilia patients with or without inhibitors against factor VIII products, which have been used for the treatment of hemophilia. Because TFPI is a negative regulator in the extrinsic coagulation pathway, neutralization of TFPI function by MG1113 can potentially increase coagulation activity by bypassing the intrinsic coagulation pathway, which factor VIII activates. OBJECTIVES: This study aims to determine the correlation between pharmacokinetics (PK) and pharmacodynamics (PD) after administering MG1113 to monkeys and to predict the PK and PD of MG1113 in humans by the Target-Mediated Drug Disposition (TMDD) model using the results from monkeys. METHODS: The PK profile of MG1113 and the PD effect on the free TFPI level were evaluated after intravenous (IV) and subcutaneous (SC) administrations of MG1113 (2.5, 5, and 10 mg/kg) to male cynomolgus monkeys. After setting up the PK/PD model on monkeys, PK parameters on humans were calculated using allometric scaling, and then clinically effective doses were predicted applying the TMDD model. RESULTS AND CONCLUSIONS: MG1113 showed nonlinear PK after both IV and SC administrations at the dosing range from 2.5 to10 mg/kg. The concentrations of MG1113 versus TFPI could be characterized a dose-response relationship using a TMDD model. The TMDD modeling and simulation built in this study were used to simulate various dosage regimens of MG1113 to apply to the first-in-human study design, and moreover expected to be referred to establish the dose for further clinical trials.
引用
- Kwak EY, Kim MJ, Park JH, et al. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics. J Thromb Haemost. 2021. PMID: 33448093. doi:10.1111/jth.15244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。